The treatment of pulmonary fibrosis;Traitement de la fibrose pulmonaire

Presse Medicale

Volumn 31, Issue 34, 2002, Pages 1613-1623

  Cottin, Vincent ^a  

^a LOUIS PRADEL HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; ARTIFICIAL LUNG SURFACTANT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; GAMMA1B INTERFERON; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; KERATINOCYTE GROWTH FACTOR; MEVINOLIN; PENICILLAMINE; PIRFENIDONE; PREDNISOLONE; PREDNISONE; RELAXIN; UNCLASSIFIED DRUG;

ACCURACY; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DYSPNEA; EPITHELIUM CELL; FIBROGENESIS; GENE THERAPY; HISTOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; LUNG BIOPSY; LUNG FIBROSIS; LUNG INFILTRATE; LUNG TRANSPLANTATION; PATHOPHYSIOLOGY; RESPIRATORY FUNCTION; REVIEW; SIDE EFFECT; SYMPTOM; THORAX RADIOGRAPHY;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PREGNANCY; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0037137109     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-25. Review.
2. Bjoraker JA, Ryu JH, Edwin MK et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
3. Liebow A. Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 1975; 8: 1-31.
4. Katzenstein AL. Myers JL Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-15.
5. Costabel U, King TE, International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J 2001; 17: 163-7.
6. King TE Jr, Costabel U, Cordier JF et al. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000, 161: 646-64.
7. Cottin V, Donsbeck AV, Revel D, Loire R, Cordier JF. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998; 158: 1286-93.
8. Katzenstein ALA, Fiorelli RF. Nonspecific interstitial pneumonia fibrosis. Histological features and clinical significance. Am J Surg Pathol 1994; 18: 136-47.
9. Cottin V, Loire R, Chalabreysse L, Thivolet F, Cordier JF. Pneumopathie interstitielle non spéfique: une nouvelle entité au sein des pneumopathies interstitielles diffuses idiopathiques. Rev Mal Respir 2001; 18: 25-33.
10. Chan ED, Worthen GS, Augustin A, Lapadat R, Riches DWH. Inflammation in the pathogenesis of interstitial lung diseases. In: Schwarz MI, King TE Jr, editors. Interstitial lung disease. Third edition ed. Hamilton (Ontario): B.C. Decker Inc.; 1998; 140-69.
11. Keogh BA, Crystal RG. Alveolitis: the key to the interstitial lung disorders. Thorax 1982; 37: 1-10.
12. Wallaert B, Lamblin C. Fibrose pulmonaire idiopathique: de la biopathologie au traitement. Rev Prat 2000; 50: 1906-10.
13. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
14. Sheppard D. Pulmonary fibrosis: a cellular overreaction or a failure of communication? J Clin Invest 2001; 107: 1501-2.
15. Peyrol S, Cordier JF, Grimaud JA. Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol 1990; 137: 155-70.
16. Cordier JF. Fibroses pulmonaires. Médecine/sciences 1994; 10: 1223-33.
17. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996; 110: 1058-67.
18. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-80.
19. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124: 1-8.
20. Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972, 27: 535-42.
21. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-9.
22. Keogh BA, Bernardo J, Hunninghake GW, Line BR, Price DL, Crystal RG, Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am Rev Respir Dis 1983; 127: 18-22.
23. Gulsvik A, Kjelsberg F, Bergmann A, Froland SS, Rootwelt K, Vale JR. High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study. Respiration 1986; 50: 252-7
24. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-15.
25. Myers JL. NSIP, UIP, and the ABCs of idiopathic interstitial pneumonias. Eur Respir J 1998; 12: 1003-4.
26. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. Am J Respir Crit Care Med 1999; 160: 1771-7.
27. King TEJr. Idiopathic pulmonary fibrosis. In: Schwarz MI, King TE Jr, editors. Interstitial lung disease. Third edition ed. Hamilton (Ontario): B.C. Decker Inc 1998; 597-644.
28. Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: 349-55.
29. Winterbauer RH, Hammar SP, Hallman KO et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1978; 65: 661-72.
30. Wright PH, Heard BE, Steel SJ, Turner-Warwick M. Cryptogenic fibrosing aiveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features. Br J Dis Chest 1981; 75: 61-70.
31. Haslam PL, Turton CWG, Lukoszek A et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35: 328-39.
32. Watters LC, Schwarz MI, Cherniack RM et al. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135: 696-704.
33. Fireman E, Vardinon N, Burke M et al. Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis. Eur Respir J 1998; 11: 706-11.
34. Flaherty KR, Toews GB, Lynch JP 3rd et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110: 278-82.
35. Collard HR, King TE Jr. Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. Am J Med 2001; 110: 326-8.
36. Raghu G, Depaso WJ, Cain K et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-6.
37. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M, Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-8.
38. Michaelson JE, Aguayo SM, Roman J. Idiopathic pulmonary fibrosis: a practical approach for diagnosis and management. Chest 2000; 118: 788-94.
39. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102: 1090-4.
40. Kolb M, Kirschner J, Riedel W, Wirtz H, Schmidt M. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 1998; 12: 1409-14.
41. Zisman DA, Lynch JP 3rd, Toews GB, Kazerooni EA, Flint A, Martinez FJ. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117: 1619-26.
42. Alton EW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 1989; 83: 277-9.
43. Fukazawa M, Kawano M, Hisano S, Ueda K, Matsuba K. Efficacy of cyclosporin A for idiopathic pulmonary fibrosis. Eur J Pediatr 1990; 149: 441-2.
44. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46: 592-5.
45. Goldstein RH, Fine A. Potential therapeutic initiatives for fibrogenic lung diseases. Chest 1995; 108; 848-55.
46. Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 915-18.
47. Phan SH. New strategies for treatment of pulmonary fibrosis. Thorax 1995; 50: 415-21.
48. Raghu G. Idiopathic pulmonary fibrosis: a need for treatment with drugs other than corticosteroids-a role for antifibrotic agents? Mayo Clin Proc 1997; 72: 285-7.
49. Schwarz MI, Treatment of IPF. What does the future hold? Chest 1995; 108: 601-2.
50. Entzian P, Schlaak M, Seitzer U, Bufe A, Acil Y, Zabel P. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175: 41-51.
51. Rennard SI, Bitterman PB, Ozaki T, Rom WN, Crystal RG. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach ot the fibrotic disorders. Am Rev Respir Dis 1988; 137: 181-5.
52. Peters SG, McDougall JC, Douglas WW, Coles DT, DeRemee RA. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103: 101-4.
53. Douglas WW, Ryu JH, Bioraker JA et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72:201-9.
54. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161: 1172-8.
55. Selman M, Carrillo G, Salas J et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114: 507-12.
56. Douglas WW, Ryu JH, Swensen SJ et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998; 158: 220-5.
57. Herbert CM, Lindberg KA, Jayson MI, Bailey AJ. Biosynthesis and maturation of skin collagen in scleroderma, and effect of D-penicillamine. Lancet 1974; 1: 187-92.
58. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276: L311-8.
59. Paulnock DK Demick KP, Coller SP. Analysis of interferon-gamma-dependent and -independent pathways of macrophage activation. J Leukoc Biol 2000; 67: 677-82.
60. Guruieyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791-808.
61. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b band low-dose prednisoione in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-9.
62. Unemorl EN, Pickford LB, Salles AL et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-45.
63. Unemori EN, Beck LS, Lee WP et al. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 1993; 101: 280-5.
64. Raghu G, Bozic CR, Brown K et al. Trial of interferon beta-1a (IFN-β1a) in idioapathic pulmonary fibrosis (IPF): characteristics of patients with and without surgical surgical lung biopsy. Am J Respir Crit Care Med 2000; 161: A527.
65. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman R Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999; 159: 220-7.
66. Vazquez de Lara L, Becerril C, Montano M et al. Surfactant components modulate fibroblast apoptosis and type I collagen and col]agenase-1 expression. Am J Physiol Lung Cell Mol Physiol 2000; 279: L950-7.
67. Chen G, Oh S, Monia BP, Stacey DW. Antisense oligonucleotides demonstrate a dominant role of c-KiRAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996; 271: 28259-65.
68. Cantin AM, Hubbard RC Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370-2.
69. Hagiwara SI, Ishii Y, Kitamura S, Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 2000; 162: 225-31.
70. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897-901.
71. Ulich TR, Yi ES, Longmuir K et al. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 1994; 93: 1298-306.
72. Panos RI, Rubin JS, Csaky KG, Aaronson SA, Mason RJ. Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. J Clin Invest 1993; 92: 969-77.
73. Yano T, Deterding RR, Simonet WS, Shannon JM, Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol 1996; 15: 433-42.
74. Uhal BD, Gidea C, Bargout R et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol 1998; 275: L1013-7.
75. Nguyen L, Ward WF, Ts'ao CH, Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med 1994; 205: 80-4.
76. Kuwano K, Hagimoto N, Kawasaki M et al. Essential roies of the Fas-Fas iigand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104: 13-9.
77. Hiwatari N, Shimura S, Sasaki T et al. Prognosis of idiopathic pulmonary fibrosis in patients with mucous hypersecretion. Am Rev Respir Dis 1991; 143: 182-5.
78. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103.
79. Cottin V, Cordier JF. Pneumopathies interstitielles diffuses idiopathiques. Rev Prat 2000; 50: 1901-5.
80. Daniil ZD, Gilchrist FC, Nicholson AG et al. A histological pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899-905.
81. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing aiveolitis. Am J Respir Crit Care Med 2000; 162: 2213-7.
82. Travis WD, Matsui K, Moss J, Ferrans VJ. idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24: 19-33.
83. Cordier JF. Organising pneumonia. Thorax 2000; 55: 318-28.
84. Bouros D, Nicholson AC, Polychronopoulos V, du Bois RM. Acute interstitial pneumonia. Eur Respir J 2000; 15: 412-8.
85. Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia: a clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986; 10: 256-67.
86. Vourlekis JS, Brown KK, Cool CD et al. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore) 2000; 79:369-78.
87. Fujita J, Yamadori I, Suemitsu I et al. Clinical features of non-specific interstitial pneumonia. Respir Med 1999; 93: 113-8.
88. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-76.
89. Wells AU, Culiinan P, Hansell DM et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-90.
90. King TEJr. Connective tissue disease. In: Schwarz MI, King TE Jr, editors. Interstitial lung disease. Second edition ed. Hamilton (Ontario): B.C. Decker Inc. 1998; 451-505.
91. Rosner S, Ginzler EM, Diamond HS et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982; 25: 612-7.
92. Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 1988; 93: 114-18.
93. Matthay RA, Schwarz MI, Petty TL et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975; 54: 397-409.
94. Tazelaar HD, Viggiano RW, Pickersglil J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141: 727-33.
95. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
96. Stern JB, Mal H, Groussard O et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest 2001; 120: 213-9.
97. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001; 120: 209-12.
98. Meyers BF, Lynch JP, Truiock EP, Guthrie T, Cooper JD, Patterson GA. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 2000; 120: 99-107.
99. Reynaud-Gaubert M, Pison C, Stern M et al. Indications de la transplantation pulmonaire et cardiopulmonaire chez l'adulte. Rev Mal Respir 2000; 17: 1119-32.
100. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis. To biopsy or not to biopsy. Am J Respir Crit Care Med 2001; 164: 185-6.